Biogen to Highlight Breadth of Alzheimer’s Disease Portfolio at AAIC 2026, Including Phase 2 CELIA Data for Diranersen

Diranersen presentation will feature Phase 2 CELIA data in early Alzheimer’s disease, including clinical, biomarker and safety results for Biogen’s investigational tau-targeting ASO, following topline results announced in May 2026 Lecanemab presentations will highlight emerging data on subcutaneous administration and real-world use, including practical treatment considerations, at-home administration, three-year LEADER data, maintenance dosing and patient experience Advances across Biogen’s Alzheimer’s disease portfolio underscore its leadership and continued commitment to innovation in Alzheimer’s care, spanning treatment delivery, real-world evidence and approaches targeting core pathologies, including amyloid and tau

The release as fetched from its publisher. biogen.com ↗